Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
06. Dezember 2024 12:01 ET
|
Rapport Therapeutics, Inc.
Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
14. November 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule...
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
07. November 2024 07:00 ET
|
Rapport Therapeutics, Inc.
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing;...
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
04. November 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule...
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
05. September 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
29. August 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
08. August 2024 07:00 ET
|
Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
29. Juli 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12. Juni 2024 16:01 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Rapport Therapeutics Announces Pricing of Initial Public Offering
06. Juni 2024 18:54 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...